Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.
All methods for the detection of factor VIII (FVIII) inhibitors are based on the measurement of inactivation of FVIII in a mixture of the test plasma containing the putative inhibitor and an exogenous source of FVIII. Various types of assays have been developed since the first inhibitor was described in 1941. Nowadays, two methods are preferably used, the Bethesda assay and the Nijmegen assay. Although the Nijmegen assay shows a better specificity and intra- and interlaboratory variation, it is still hampered by several limitations related to assay characteristics (pH, temperature, and time of incubation), type of control sample, and the von Willebrand factor content of the assay mixture. Epitope specificity plays an important role in the reliability of functional assays because inhibitors against the C2 domain are more difficult to quantify compared with inhibitors against the A2 domain. Finally, lupus anticoagulants can interfere with inhibitor assays, resulting in aberrant results. This report describes in detail the various problems encountered with the assays used in the quantification of functional FVIII inhibitors.
Verbruggen
Bert
B
Department of Laboratory Medicine, Laboratory of Hematology, Nijmegen, The Netherlands. h.verbruggen@chl.umcn.nl
van Heerde
Waander L
WL
Laros-van Gorkom
Britta A P
BA
D019774:Blood Coagulation Factor Inhibitors / Q000032:analysis / Q000276:immunology*; D001780:Blood Coagulation Tests / Q000379:methods* / Q000592:standards; D000939:Epitopes / Q000276:immunology; D005169:Factor VIII / Q000276:immunology*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D011785:Quality Assurance, Health Care
D019774:Blood Coagulation Factor Inhibitors; D000939:Epitopes; D016682:Lupus Coagulation Inhibitor; D005169:Factor VIII